OCWP
MYGN icon

Owl Creek Wealth Partners’s Myriad Genetics MYGN Stock Holding History

Owl Creek Wealth Partners’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$286 Sell
50
-900
-95% -$4.08K ﹤0.01% 1268
2026
Q1 		$4.28K Buy
+950
New +$4.95K ﹤0.01% 1000

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Owl Creek Wealth Partners's MYGN Position: Q2 2026 in Review

Owl Creek Wealth Partners reduced its Myriad Genetics (MYGN) stake by 95% in Q2 2026, selling an estimated $4.08K and leaving 50 shares worth $286. The position accounts for ﹤0.01% of the portfolio, ranked #1268.

Owl Creek Wealth Partners first reported a position in MYGN in Q1 2026 and has held it in 2 quarters since. The position peaked at $4.28K in Q1 2026. 183 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

  • Owl Creek Wealth Partners held 50 shares of Myriad Genetics worth $286 as of Q2 2026.
  • Owl Creek Wealth Partners sold 900 Myriad Genetics shares in Q2 2026, an estimated $4.08K.
  • Myriad Genetics made up ﹤0.01% of Owl Creek Wealth Partners's portfolio in Q2 2026, its #1268 holding.
  • Owl Creek Wealth Partners first reported a position in Myriad Genetics in Q1 2026 and has held it in 2 quarters since.
  • Owl Creek Wealth Partners's Myriad Genetics position peaked at $4.28K in Q1 2026.
  • 183 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Owl Creek Wealth Partners's 13F filing for Q2 2026, filed 20 Jul 2026.